MX364864B - Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante. - Google Patents

Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante.

Info

Publication number
MX364864B
MX364864B MX2014008857A MX2014008857A MX364864B MX 364864 B MX364864 B MX 364864B MX 2014008857 A MX2014008857 A MX 2014008857A MX 2014008857 A MX2014008857 A MX 2014008857A MX 364864 B MX364864 B MX 364864B
Authority
MX
Mexico
Prior art keywords
drug formulation
injectable drug
time released
depot
microparticles suspended
Prior art date
Application number
MX2014008857A
Other languages
English (en)
Spanish (es)
Other versions
MX2014008857A (es
Inventor
A Marsh David
Ma Rivers Hongwen
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2014008857A publication Critical patent/MX2014008857A/es
Publication of MX364864B publication Critical patent/MX364864B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2014008857A 2012-01-23 2013-01-22 Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante. MX364864B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261589681P 2012-01-23 2012-01-23
PCT/US2013/022466 WO2013112434A1 (en) 2012-01-23 2013-01-22 Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation

Publications (2)

Publication Number Publication Date
MX2014008857A MX2014008857A (es) 2015-07-17
MX364864B true MX364864B (es) 2019-05-09

Family

ID=47630595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008857A MX364864B (es) 2012-01-23 2013-01-22 Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante.

Country Status (17)

Country Link
US (5) US20130189369A1 (https=)
EP (1) EP2806853B1 (https=)
JP (1) JP6282231B2 (https=)
KR (5) KR102183727B1 (https=)
CN (1) CN104136006B (https=)
AU (3) AU2013212583A1 (https=)
BR (1) BR112014017969A8 (https=)
CA (1) CA2861348C (https=)
DK (1) DK2806853T3 (https=)
ES (1) ES2821526T3 (https=)
HU (1) HUE050904T2 (https=)
IL (2) IL233620A0 (https=)
MX (1) MX364864B (https=)
NZ (1) NZ627368A (https=)
RU (1) RU2672596C2 (https=)
WO (1) WO2013112434A1 (https=)
ZA (1) ZA201405091B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014017969A8 (pt) * 2012-01-23 2017-07-11 Allergan Inc Microesferas ou micropartículas bioerodíveis ou bio-degradáveis liberadas por tempo suspensas em uma formulação de droga injetável de formação de depósito
US20150335704A1 (en) * 2014-05-23 2015-11-26 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
US20170112936A1 (en) * 2014-05-23 2017-04-27 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions comprising gels and methods for fabricating thereof
CN104306330A (zh) * 2014-09-24 2015-01-28 万特制药(海南)有限公司 一种盐酸美金刚缓释混悬液及其制备方法
EP3352735B1 (en) 2015-09-21 2023-08-30 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulations
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治疗的聚集性微粒
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
US10668011B2 (en) 2016-06-30 2020-06-02 Durect Corporation Depot formulations
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
CA3069159A1 (en) * 2017-07-11 2019-01-17 Sustained Nano Systems Llc Hypercompressed pharmaceutical formulations
CN107595765A (zh) * 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
GB2586975B (en) * 2019-09-09 2024-03-06 Roemex Ltd Device and method for use with subsea pipelines
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
WO2022198167A1 (en) * 2021-03-15 2022-09-22 Oakwood Laboratories, Llc Microsphere formulations comprising naltrexone and methods for making and using the same
JP2024529009A (ja) 2021-07-06 2024-08-01 マーク・ヘースルトン セロトニン再取り込み阻害剤離脱症候群の治療
CN116869914A (zh) * 2023-05-30 2023-10-13 庄秉谚 无针注射系统的投递物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
JP4259610B2 (ja) * 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
JP4642946B2 (ja) * 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
CN1314452C (zh) * 2002-04-22 2007-05-09 沈阳药科大学 具有适宜相转变温度的眼用原位凝胶制剂
CN100453066C (zh) * 2002-12-04 2009-01-21 参天制药株式会社 利用结膜下储存库的药物释放系统
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
UA96342C2 (en) * 2007-06-25 2011-10-25 Оцука Фармасьютикал Ко., Лтд. Microspheres having core/shell structure
KR20120095371A (ko) * 2009-10-01 2012-08-28 에보닉 데구사 코포레이션 노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법
CN101816627B (zh) * 2010-04-16 2012-03-07 浙江大学 一种协同治疗型多物质缓释滴眼剂及制备方法
CN102100663B (zh) * 2011-01-14 2013-04-17 华南理工大学 一种pH敏感型原位凝胶纳米缓释眼药水的制备方法
BR112014017969A8 (pt) * 2012-01-23 2017-07-11 Allergan Inc Microesferas ou micropartículas bioerodíveis ou bio-degradáveis liberadas por tempo suspensas em uma formulação de droga injetável de formação de depósito

Also Published As

Publication number Publication date
CA2861348A1 (en) 2013-08-01
MX2014008857A (es) 2015-07-17
US20240423922A1 (en) 2024-12-26
RU2672596C2 (ru) 2018-11-16
KR102183727B1 (ko) 2020-11-27
DK2806853T3 (da) 2020-09-28
HUE050904T2 (hu) 2021-01-28
HK1204765A1 (en) 2015-12-04
NZ627368A (en) 2016-11-25
EP2806853A1 (en) 2014-12-03
ZA201405091B (en) 2015-12-23
ES2821526T3 (es) 2021-04-26
CA2861348C (en) 2017-07-04
JP2015504098A (ja) 2015-02-05
EP2806853B1 (en) 2020-07-08
IL233620A0 (en) 2014-08-31
RU2014134420A (ru) 2016-03-20
AU2019204957A1 (en) 2019-07-25
AU2013212583A1 (en) 2014-08-14
KR20200073292A (ko) 2020-06-23
IL265620B (en) 2022-03-01
IL265620A (en) 2019-05-30
KR20220044379A (ko) 2022-04-07
US20130189369A1 (en) 2013-07-25
BR112014017969A2 (https=) 2017-06-20
CN104136006B (zh) 2017-11-24
JP6282231B2 (ja) 2018-02-21
KR20200133286A (ko) 2020-11-26
KR20140114892A (ko) 2014-09-29
WO2013112434A1 (en) 2013-08-01
CN104136006A (zh) 2014-11-05
US20200297650A1 (en) 2020-09-24
BR112014017969A8 (pt) 2017-07-11
KR20230104761A (ko) 2023-07-10
AU2017258895B2 (en) 2019-04-18
AU2017258895A1 (en) 2017-11-30
US20230390212A1 (en) 2023-12-07
US20240226022A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
MX364864B (es) Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante.
PH12014500827A1 (en) Smoking article with liquid delivery material
EP2833849A4 (en) INTRAOCULAR RELEASE DEVICES AND METHOD THEREFOR
ZA201705792B (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
MX2019002575A (es) Microcapsulas biodegradables que contienen material de relleno.
MX352907B (es) Composiciones de un poliortoéster y un solvente aprótico.
PH12016501061A1 (en) Smoking article with liquid release component having frangible shell
PH12016500691A1 (en) Smoking article with liquid release component
EP2563338A4 (en) HIGH SHEAR APPLICATION USED FOR DRUG DELIVERY
IL240148A0 (en) Biodegradable and clinically compatible nanoparticles as drug delivery carriers
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
PH12016500706A1 (en) Smoking article with liquid delivery material
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
MX2016009493A (es) Sistemas trasdermicos restrictivos de abuso y mal uso.
EP2925340B8 (en) Pharmaceutical compositions comprising selective agonists of melanocortin 1 receptor and their use in therapeutic methods
MY179519A (en) Smoking article with tactile liquid release component
AR086346A1 (es) Proceso para producir un material inorganico particulado
MX341642B (es) Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
WO2014060443A3 (en) A composite scaffold for use as a tissue engineering implant
EP2949723A4 (en) RESIN COMPOSITION, COATED PARTICLES, INJECTION MEANS AND METHOD OF INJECTING AN INJECTION AGENT INTO A FRACTURE
PH12015501533A1 (en) Controlled release formulations of lorazepam
GB201322869D0 (en) Therapeutic agents and delivery with microspheres
王美丽 et al. Angiotensin Ⅱ destabilizes Cartilage Oligomeric Matrix Protein m RNA via upregulating AUF-1
HK1235660A1 (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
UA101837C2 (ru) Инъекционное средство с иммуностимулирующими и общеукрепляющими свойствами на основе меда

Legal Events

Date Code Title Description
FG Grant or registration